Zakrzewski Joseph S's Form 4 filing
Cyteir Therapeutics, Inc. (CYT) · filed Dec 28, 2021
- Accession no.
- 0000899243-21-049973
- Filed
- Dec 28, 2021
- Trade date
- Dec 23-28, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $10.9K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zakrzewski Joseph SCIK 0001331852 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2021 | Common Stock | PPurchaseAcquired | +200 | $9.87 | +$1,974 | 81,367 | Direct | |
| Dec 27, 2021 | Common Stock | PPurchaseAcquired | +200 | $9.97 | +$1,994 | 81,567 | Direct | |
| Dec 27, 2021 | Common Stock | PPurchaseAcquired | +99 | $10.18 | +$1,007.82 | 81,666 | Direct | |
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +601 | $9.85F2 | +$5,919.85 | 82,267 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.81 to $9.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.